NORTHPOINTE BANCSHARES INC Q2 FY2024 earnings call

• Divested operations in China on April 2, extinguished $183 million of redemption obligations and later an additional $17 million, transitioning to a U.S.-based global biotech. • Streamlined organization, built a new U.S.-based leadership team including CFO Joe Skelton and CMO Phillip Dennis, and engaged PWCUS as corporate auditor. • Significantly advanced three oncology programs: uliledlimab, givastomig, and ragistomig with upcoming milestones; uliledlimab expects to initiate a frontline combination study in H1 2025, givastomig to present updated Phase I monotherapy data at ESMO 2024, and ragistomig showed early positive data at ASCO 2024.

No detailed financial performance by product segments with absolute terms and revenue contribution % provided in the transcript.

• Cash runway expected to take I-MAB into 2027. • Expect to present updated Phase I dose expansion data for givastomig at ESMO 2024. • Anticipate initiating first patient dose in the uliledlimab combination study in patients with advanced non-small cell lung cancer in H1 2025. • Expect top line data from the givastomig combo study in gastric cancers in H2 2025. • Expect top line progression-free survival data from the randomized Phase II study by TJ Bio for uliledlimab in H2 2025.

Q: Joe Catanzaro asked about the upcoming ESMO update for givastomig and comparison to Claudin 18.2 ADC landscape.

A: Phillip Dennis stated the ESMO data will be from dose expansion cohorts with gastric cancer, noting exquisite safety and ORR, and that giva's tolerability makes it well-suited for combination with frontline therapy like nivolumab and Folfox, differentiating from ADCs with better tox profile for combination use.

Q: Unknown Analyst inquired about targeted finish date for transitioning to U.S.-based auditor, expenses split, and pipeline strategy.

A: Sean Fu responded that PWCUS is now the corporate auditor, going burn rate will be lower due to streamlined organization, and the team is actively looking to license in and collaborate on oncology-focused assets with potential for adjacent therapeutic areas.

Q: Andres Maldonado asked about efficacy benchmarks for uliledlimab combination study and leveraging data from TJ Bio study.

A: Phillip Dennis mentioned benchmarks against Keynote 189, focusing on clinically meaningful improvements, and external signals from competitor studies validating the adenosine pathway, with interest in outcomes from studies with other CD73-targeted assets to support uli's hypothesis.